Skip to content

Liquidia

US · LQDA #2623 by market cap Listed 2018
54.43 -2.20 -3.88%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio -203.58 Cheap vs history 0th percentile
5-year average 29.49 · #66 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -54.68 Cheap vs history 0th percentile
5-year average 13.21 · forward 15.48 · #17 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 8.32 Cheap vs history 2nd percentile
5-year average 44.64 · forward 5.54 · #66 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Liquidia (LQDA) 4.90B -51.84 -193.01 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value46.16 Economic moatNarrow UncertaintyHigh

Trading 15.2% above Morningstar's fair value estimate.

Fair value

Liquidia Corp receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 24% premium over our quantitative fair value estimate of $46.16 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 4.9%, which falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

Conversely, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's enterprise value to free cash flow ratio of 18.6, a core component of profitability, sits in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is overvalued, this outperformance had a positive impact on our valuation estimate.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.

Liquidia discussion 0 comments

Add a comment